EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut microbial metabolites in colorectal cancer: dual roles in tumorigenesis, immune crosstalk, and therapeutic innovation

Yutao Jin, He Zhu, Jiawei Fan, Hong Xu

Frontiers in Cellular and Infection Microbiology · 2026

DOI: 10.3389/fcimb.2026.1693161 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Yutao Jin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Gastrointestinal Microbiome, Carcinogenesis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A substantial body of evidence has elucidated the critical role of gut microbiota in the development and progression of colorectal cancer (CRC). Gut dysbiosis, defined as the disruption of microbiome homeostasis, has been implicated in the pathogenesis of various diseases, including CRC, Parkinson’s disease, and autoimmune liver disorders. In recent years, research has increasingly focused on microbial metabolites, with numerous studies confirming their association with CRC. This review systematically elucidates the dual roles of microbial metabolites in the initiation and progression of CRC: they can suppress tumors by strengthening the gut barrier, reducing inflammation, blocking abnormal cell growth, and triggering apoptosis; yet under dysbiotic conditions-like chronic inflammation or epithelial injury-they may promote cancer by releasing inflammatory cytokines, damaging DNA, and driving uncontrolled proliferation. We summarize key findings on these metabolites’ functions in CRC, highlight emerging metabolite-targeted therapies, and identify major hurdles to clinical translation: metabolite instability, individual variation in host-microbe interactions, and absent biomarkers for patient selection. Because the gut microbiota-metabolite axis is central to CRC biology, targeting it rationally offers a promising path to more precise and effective treatments. Ultimately, gut metabolites are not just disease indicators-they are actionable therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsGastrointestinal MicrobiomeCarcinogenesisHumansAnimalsDysbiosisHost Microbial Interactions

Stichwörter der Autor:innen

amino acids and amino acid-related metabolitesbile acidscolorectal cancermetabolitesshort-chain fatty acid

Autor:innen und Institutionen

  • Department of Gastroenterology, The First Hospital of Jilin University, Changchun, China.

Zitieren

APA

Jin, Y., Zhu, H., Fan, J., & Xu, H. (2026). Gut microbial metabolites in colorectal cancer: dual roles in tumorigenesis, immune crosstalk, and therapeutic innovation. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1693161

Vancouver

Jin Y, Zhu H, Fan J, Xu H. Gut microbial metabolites in colorectal cancer: dual roles in tumorigenesis, immune crosstalk, and therapeutic innovation. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1693161

BibTeX
@article{Jin2026,
  author = {Jin, Yutao and Zhu, He and Fan, Jiawei and Xu, Hong},
  title = {Gut microbial metabolites in colorectal cancer: dual roles in tumorigenesis, immune crosstalk, and therapeutic innovation},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  doi = {10.3389/fcimb.2026.1693161}
}
Kostenlos starten →